难以治疗的性结肠炎患者的临床特征:使用日本索赔数据库进行的嵌套病例对照研究
Katsuyoshi Matsuoka1, Ataru Igarashi2,3, Noriko Sato4
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan.
Intestinal research
|April 25, 2025
概括
难以治疗的性结肠炎 (D2T UC) 影响了开始先进治疗的患者中的16.7%. 在治疗前服用高剂量的皮质类固醇可预测D2TUC,这表明需要更密切的监测.
科学领域:
- 胃肠病学 胃肠病学
- 临床流行病学临床流行病学
- 药物治疗 药物治疗
背景情况:
- 先进的治疗方法改善了性结肠炎 (UC) 管理.
- 然而,有一部分患者会出现难以治疗的D2TUC.
- 了解D2T UC特征对于优化患者护理至关重要.
研究的目的:
- 定义D2T UC的流行病学和临床特征.
- 在开始先进治疗的患者中确定D2TUC的预测因子.
主要方法:
- 使用大型索赔数据库进行嵌套病例控制研究 (2018年1月-2023年4月).
- 定义D2T UC为≥2次先进治疗切换或手术,在第一个先进治疗后2年内进行.
- 1:1对D2T UC和非D2T UC患者进行分析.
主要成果:
- 16.7%的UC患者开始先进治疗被归类为D2TUC.
- 在先进治疗前6个月中,更高的基线皮质类固醇剂量 (≥30毫克/天) 与D2TUC显著相关.
- D2T UC患者的第一个先进治疗持续时间较短,更频繁的切换.
结论:
- 尽管有先进的治疗方法,但很大一部分UC患者会发展D2TUC.
- 开始前的皮质类固醇剂量是D2TUC的关键预测因素.
- 早期识别患有D2TUC风险的患者可以指导治疗策略.
更多相关视频
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
94
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
94
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
236
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
236
Chronic Bowel Disorders: Introduction
310
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
310
Drugs for Treatment of Ulcerative Colitis in IBD
102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
64
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
64
Inflammatory Bowel Disease II: Crohn's Disease
127
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
127


